問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Nephrology

更新時間：2023-09-19

邱鼎育
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱鼎育

List

24Cases

2021-09-21 - 2026-06-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-09-30 - 2026-06-30

Phase II

Active
A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    tablets

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2022-05-02 - 2026-09-30

Phase III

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    Sibeprenlimab (VIS649) Sibeprenlimab (VIS649)

Participate Sites
6Sites

Recruiting6Sites

2017-01-01 - 2018-12-31

Phase IV

A Long-Term, Open-Label, Prospective Observational Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects with End Stage Renal Disease (ESRD) on Dialysis.

  • Condition/Disease

    Hyperphosphatemia/End Stage Renal Disease (ESRD)

  • Test Drug

    NEPHOXIL®

Participate Sites
9Sites

Terminated9Sites

2016-12-01 - 2021-11-30

Phase III

A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa

  • Condition/Disease

    non-dialysis with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Recruiting7Sites

Terminated5Sites

蘇裕謀
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Nephrology

2016-12-01 - 2020-12-31

Phase III

ASCEND-D: A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents

  • Condition/Disease

    dialysis subjects with anemia associated with chronic kidney disease

  • Test Drug

    Daprodustat (GSK1278863)

Participate Sites
12Sites

Terminated12Sites

2020-11-30 - 2022-03-28

Phase II

A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)

  • Condition/Disease

    Membranous Nephropathy

  • Test Drug

    MOR202

Participate Sites
5Sites

Recruiting5Sites

2017-07-01 - 2020-02-16

Phase III

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

  • Condition/Disease

    Atypical Hemolytic Uremic Syndrome (aHUS)

  • Test Drug

    ALXN1210

Participate Sites
4Sites

Terminated4Sites

2009-10-12 - 2010-08-17

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-08-01 - 2010-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB